J. Anderl

发表

Effect of conjugation site and technique on the stability and pharmacokinetics of antibody-drug conjugates.

R. Kellner, H. Kolmar, C. Schröter, 2021, Journal of pharmaceutical sciences.

Site-specific conjugation of native antibodies using engineered microbial transglutaminases.

S. Hecht, J. Dotterweich, C. Schroeter, 2020, Bioconjugate chemistry.

Immunoproteasome functions explained by divergence in cleavage specificity and regulation

A. Sali, C. Craik, Peter Cimermancic, 2017, eLife.

Antibody-drug conjugate payloads.

M. Kulke, H. Faulstich, J. Anderl, 2013, Methods in molecular biology.

Enhanced Dendritic Cell Development Through Long-Term Proteasome Inhibition

W. Lems, S. E. Verbrugge, G. Jansen, 2018 .

Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.

Y. Assaraf, G. Jansen, J. Cloos, 2014, Biochemical pharmacology.

Signal peptide mimicry primes Sec61 for client-selective inhibition

J. Taunton, C. Kalyanaraman, J. Huiskonen, 2022, bioRxiv.

Antibody-drug conjugates: what drives their progress?

U. Haberkorn, W. Mier, Nikos Kühl, 2022, Drug discovery today.

New drugs and optimization of drug potency

M. Kulke, J. Anderl, Torsten Hechler, 2015 .

Antileukemic Activity and Mechanism of Drug Resistance to the Marine Salinispora tropica Proteasome Inhibitor Salinosporamide A (Marizomib)

B. Moore, Y. Assaraf, G. Jansen, 2014, Molecular Pharmacology.

Analysis of autophagosome formation using lentiviral biosensors for live fluorescent cellular imaging.

Haizhen Liu, Kevin Su, Mark Santos, 2015, Methods in molecular biology.

Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors

Jeremiah D. Degenhardt, Y. Assaraf, A. Schimmer, 2013, Haematologica.

Toll‐Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow‐Derived Mesenchymal Stem Cells by Inducing Indoleamine‐2,3‐dioxygenase‐1 via Interferon‐β and Protein Kinase R

M. Weller, W. Wick, Ulrike Litzenburger, 2009, Stem cells.

Analysing the Use of Fluorescent Cellular Imaging and Lentiviral Biosensors for Autophagosome Formation

Haizhen Liu, Kevin Su, Mark Santos, 2012 .

Chemical modification allows phallotoxins and amatoxins to be used as tools in cell biology

H. Faulstich, H. Echner, J. Anderl, 2012, Beilstein journal of organic chemistry.

Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.

Gerhard Moldenhauer, I. Herr, H. Faulstich, 2012, Journal of the National Cancer Institute.

Correction of Cystathionine β‐Synthase Deficiency in Mice by Treatment with Proteasome Inhibitors

M. Slifker, W. Kruger, C. Kirk, 2013, Human mutation.

A novel, non-radioactive eukaryotic in vitro transcription assay for sensitive quantification of RNA polymerase II activity

J. Anderl, C. Voss, B. Schmitt, 2014, BMC Molecular Biology.

Abstract A36: TP53 loss creates therapeutic vulnerability in colorectal cancer

Xiongbin Lu, Xiaoming He, Cristina Ivan, 2017 .

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

T. Muchamuel, M. Bennett, F. Parlati, 2011, Clinical Cancer Research.

Role of Epoxide Hydrolases and Cytochrome P450s on Metabolism of KZR-616, a First-in-Class Selective Inhibitor of the Immunoproteasome

B. Hammock, C. Morisseau, T. Muchamuel, 2021, Drug Metabolism and Disposition.

Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses

B. Tuch, T. Muchamuel, E. Lowe, 2023, Frontiers in Immunology.

A neuronal and astrocyte co-culture assay for high content analysis of neurotoxicity.

Stella Redpath, Janet L Anderl, Andrew J Ball, 2009, Journal of visualized experiments : JoVE.

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

R. Moss, R. Rifkin, Y. Ou, 2016, Blood.

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines

Y. Assaraf, J. Blank, P. M. van de Ven, 2014, Journal of Hematology & Oncology.

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

G. Peters, B. Dijkmans, W. Lems, 2013, Experimental Hematology & Oncology.

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).

T. Muchamuel, E. Lowe, C. Kirk, 2018, Journal of medicinal chemistry.

Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.

E. Bradley, T. Muchamuel, E. Lowe, 2017, ACS medicinal chemistry letters.

Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models

Amanda F Baker, A. Baker, L. Garland, 2014, Journal of experimental & clinical cancer research : CR.

Neurodegeneration Induced by Bortezomib Exposure in Vitro Occurs Via Proteasome Independent Mechanisms.

M. Bennett, S. Arastu‐Kapur, C. Kirk, 2009 .

Clinical Profile Of Single-Agent Modified-Release Oprozomib Tablets In Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

D. Siegel, R. Vij, J. Kaufman, 2013 .

A neuronal and astrocyte co-culture assay for high content analysis of neurotoxicity.

A. J. Ball, J. Anderl, Stella Redpath, 2009, Journal of visualized experiments : JoVE.

AB0509 Kzr-616, a selective inhibitor of the immunoproteasome, shows a promising safety and target inhibition profile in a phase i, double-blind, single (SAD) and multiple ascending dose (MAD) study in healthy volunteers

J. Anderl, D. Bomba, A. Fan, 2018 .

Proteasome inhibitors in acute leukemia

Y. Assaraf, J. Blank, P. M. van de Ven, 2014 .

Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors

Jeremiah D. Degenhardt, Y. Assaraf, A. Schimmer, 2013, Haematologica.